Abstract
In Japan, since August 1992, materials derived from pharmacoeconomic evaluations have been accepted at the time of new drug price negotiation. Pharmaceutical companies generally consider the materials they submit to be private information. Moreover, it is unclear how the government uses these materials in its policy decisions. In this paper, for the purpose of understanding the present status of pharmacoeconomic evaluation in Japanese pharmaceutical companies, the results from an investigative interview of selected employees at 22 pharmaceutical firms are outlined. An analysis of how the submitted economic data are reflected in drug prices is provided. This analysis clarifies that in recent years pharmacoeconomic evaluations have been submitted for most new pharmaceutical products. A clear connection between the submitted economic materials and the issuing of premiums to innovative or useful products, however, was not found. It is concluded that there is an urgent need to construct a system in which the results of pharmacoeconomic evaluation can be appropriately used in government pricing decisions.
Similar content being viewed by others
References
Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee, including major submissions involving economic analyses. Canberra: Australian Government Publishing Service; November 1995.
Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 1st Ed. Ottawa: CCOHTA; November 1994.
Drummond MF, Rutten F, Brenna A, et al. Economic evaluations of pharmaceuticals: a European perspective. PharmacoEcon. 1993;4:173–186.
Freemantle N, Maynard A. Something rotten in the state of clinical and economic evaluations. Health Econ. 1994;3:63–67.
Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
Ikeda S, Ikegami N, Oliver AJ, et al. A Case for the Adoption of Pharmacoeconomic Guidelines in Japan. PharmacoEcon. 1997;10:546–551.
Ministry of Health and Welfare. Administrative Announcement. September 30, 1994.
Moriga M, Ikeda S, Reich MR. An analysis of pharmacoeconomic studies in Japan, lryo Keizai Kenkyu. 1995;2:73–83.
Nikkan Yakugyo (Daily Pharmaceutical Industry). August 23, 1994:6.
Task Force on Principles for Economic Analysis of Health Care Technology. Economic Analysis of Health Care Technology. A Report on Principles. Ann Int Med. 1995;122:61–70.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ikeda, S., Oliver, A.J. & Ikegami, N. Pharmacoeconomic Evaluation in Japanese Pharmaceutical Companies. Ther Innov Regul Sci 32, 169–174 (1998). https://doi.org/10.1177/009286159803200124
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159803200124